Assessment of Serum Survivin Levels as a Potential Biomarker for Disease Severity and Therapeutic Outcome: Results of a Pilot Study
Kuruva Janakiramudu, Sumita Halder, Rajarshi Kar, Chander Grover, Rachna Gupta, Edelburt A. Almeida · 2026
Read Assessment of Serum Survivin Levels as a Potential Biomarker for Disease Severity and Therapeutic Outcome: Results of a Pilot Study by Kuruva Janakiramudu, Sumita Halder, Rajarshi Kar, Chander Grover, Rachna Gupta, Edelburt A. Almeida (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13588454.txt.
Description
Janakiramudu and co-authors run a pilot study of a blood marker, survivin, in people with psoriasis. Survivin blocks cell death and is suspected of feeding the overgrowth of skin cells in this chronic inflammatory disease. The study enrolled 30 patients with moderate to severe psoriasis and 30 healthy controls. Blood survivin was measured before treatment and after twelve weeks of methotrexate, alongside a standard severity score.
Patients started with survivin levels about three times those of controls. After treatment, their levels fell to near the control range, and skin severity scores dropped by about half over the same period. The size of the survivin drop tracked the size of the skin improvement closely. The authors suggest survivin could serve as a blood gauge of disease activity and treatment response. They note the study's limits plainly: it was small, brief, and lacked skin tissue checks.
Catalog record
| CREATOR | Kuruva Janakiramudu, Sumita Halder, Rajarshi Kar, Chander Grover, Rachna Gupta, Edelburt A. Almeida |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |